SCHEMBL16748613

SCHEMBL16748613

Cc1nc2ccc(F)cc2n1-c1nc(N)nc(Nc2ccc(Cl)cc2)n1

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
BMI1 P35226 5/20 0.48
AGPAT2 O15120 4/20 0.46
DHFR P00374 4/20 0.45
MAP3K14 Q99558 1/20 0.43
EGFR P00533 1/20 0.42
NPC1 O15118 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2C19 P33261 1/20 0.41
RAB9A P51151 1/20 0.41
GSR P00390 1/20 0.41
ALDH1A1 P00352 1/20 0.40
ADORA3 P0DMS8 1/20 0.40
SLC6A2 P23975 1/20 0.40
PDE4A P27815 1/20 0.40
KDR P35968 1/20 0.40
MEN1 O00255 1/20 0.39
BLM P54132 1/20 0.39
KMT2A Q03164 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16748445 0.91 BMI1 (0.50) BMI1DHFRNPC1CYP1A2CYP3A4
SCHEMBL16740734 0.90 BMI1 (0.50) BMI1AGPAT2DHFRNPC1CYP1A2
SCHEMBL16748437 0.89 BMI1 (0.48) BMI1AGPAT2DHFREGFRNPC1
SCHEMBL16748426 0.89 BMI1 (0.44) BMI1DHFRMAP3K14
SCHEMBL16740869 0.88 PIK3CD (0.48) AGPAT2DHFRMAP3K14EGFRNPC1
SCHEMBL16748533 0.87 BMI1 (0.64) BMI1AGPAT2DHFRMEN1BLM
SCHEMBL16748450 0.87 BMI1 (0.52) BMI1DHFRNPC1CYP1A2CYP3A4
SCHEMBL16748587 0.87 BMI1 (0.47) BMI1DHFRNPC1RAB9AALDH1A1
SCHEMBL16748592 0.85 EGFR (0.41) AGPAT2DHFREGFRNPC1CYP1A2
SCHEMBL16748610 0.85 BMI1 (0.49) BMI1DHFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9975878-B2 Substituted triazine BMI-1 inhibitors PTC THERAPEUTICS, INC. (US) 2018-05-22 US claimed
US-20160297798-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. 2016-10-13 US claimed
US-9975878-B2 Substituted triazine BMI-1 inhibitors PTC THERAPEUTICS, INC. (US) 2018-05-22 US disclosed
US-9975878-B2 Substituted triazine BMI-1 inhibitors PTC THERAPEUTICS, INC. (US) 2018-05-22 US disclosed
US-20160297798-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. 2016-10-13 US disclosed
US-20160297798-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. 2016-10-13 US disclosed
WO-2015076801-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. (US) 2015-05-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160297798-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS BMI1, BAZ2A, BAZ2B BMI1 1/4885AGPAT2 3973/4885DHFR 4017/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.